NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$14.32

-0.30 (-2.05%)

(As of 12/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $14.15
▼
$14.81
50-Day Range: $12.91
▼
$17.03
52-Week Range: $10.81
▼
$21.25

Volume: 508,868 shs
Average Volume: 903,654 shs
Market Capitalization: $593.09 million

P/E Ratio: 2.49
Dividend Yield: N/A
Price Target: $25.80

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 80.2% Upside
$25.80 Price Target
Short Interest: Bearish
10.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.13
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.10) to ($2.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

350th out of 1,033 stocks

Pharmaceutical Preparations Industry

141st out of 502 stocks

3.3

Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.80, Intercept Pharmaceuticals has a forecasted upside of 80.2% from its current price of $14.32.
Amount of Analyst Coverage
Intercept Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.07% of the outstanding shares of Intercept Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Intercept Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Intercept Pharmaceuticals has recently increased by 3.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Intercept Pharmaceuticals is -2.13.

2.6

News and Social Media Coverage

News Sentiment
Intercept Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Intercept Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for ICPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
4 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.00% of the stock of Intercept Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.00% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($6.10) to ($2.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is 2.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.92.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is 2.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.72.

See Top Rated MarketRank™ Stocks Here

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

December 5, 2022 | finance.yahoo.com

Analysts Expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) To Breakeven Soon

November 28, 2022 | americanbankingnews.com

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives $25.80 Average Price Target from Brokerages

November 22, 2022 | finance.yahoo.com

Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022

November 8, 2022 | finance.yahoo.com

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

November 8, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 7, 2022 | seekingalpha.com

Intercept updates Phase 3 data for the NASH candidate

November 7, 2022 | finance.yahoo.com

Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022

November 6, 2022 | finance.yahoo.com

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

November 4, 2022 | seekingalpha.com

Intercept Pharmaceuticals: Trying Times

November 2, 2022 | markets.businessinsider.com

Expert Ratings for Intercept Pharmaceuticals

November 2, 2022 | finance.yahoo.com

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

November 1, 2022 | finanznachrichten.de

Intercept Pharmaceuticals, Inc.: Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

October 30, 2022 | finance.yahoo.com

Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested three years ago

October 25, 2022 | finance.yahoo.com

Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022

October 2, 2022 | finance.yahoo.com

Institutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses

September 30, 2022 | reuters.com

Intercept Pharma's liver disease drug fails late-stage trial

September 30, 2022 | seekingalpha.com

Intercept stock slumps 18% as liver disease drug fails phase 3 trial

September 30, 2022 | marketwatch.com

Intercept Pharmaceuticals Shares Slide After NASH Study Miss >ICPT

September 30, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

September 30, 2022 | marketwatch.com

Intercept Phase 3 Compensated Cirrhosis NASH Study Misses Primary Endpoint >ICPT

September 30, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

September 26, 2022 | finance.yahoo.com

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

September 22, 2022 | markets.businessinsider.com

B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)

September 21, 2022 | finance.yahoo.com

Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning

September 21, 2022 | finance.yahoo.com

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings: 11/03/2021
Today: 12/05/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/01/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ICPT
CUSIP: 45845P10
CIK: 1270073
Web: www.interceptpharma.com
Phone: (646) 747-1000
Fax: 646-747-1001
Employees: 437
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.80
High Stock Price Forecast: $49.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +80.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.74
Trailing P/E Ratio: 2.49
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,430,000.00
Net Margins: 62.47%
Pretax Margin: -45.54%
Return on Equity: N/A
Return on Assets: -34.09%

Debt

Debt-to-Equity Ratio: 2.07
Current Ratio: 2.46
Quick Ratio: 2.46

Sales & Book Value

Annual Sales: $363.47 million
Price / Sales: 1.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.23) per share
Price / Book: -2.30

Miscellaneous

Outstanding Shares: 41,417,000
Free Float: 32,719,000
Market Cap: $593.09 million
Optionable: Optionable
Beta: 1.15

Key Executives

Mr. Jerome B. Durso (Age 54)
Pres, CEO & Director
Comp: $1.16M

Mr. Andrew Saik (Age 53)
Chief Financial Officer
Comp: $485.07k

Mr. Rocco Venezia (Age 46)
Chief Accounting Officer & Treasurer
Comp: $660.62k

Mr. Jared M. Freedberg J.D. (Age 54)
Gen. Counsel
Comp: $691.46k

Dr. M. Michelle Berrey M.D. (Age 55)
M.P.H., MPH., Pres of R&D and Chief Medical Officer
Comp: $732.13k

Mr. Nareg Sagherian
Exec. Director of Global Investor Relations

Mr. David Ford (Age 52)
Chief HR Officer

Dr. Mark Pruzanski M.D. (Age 54)
Founder, Advisor & Director

Ms. Linda M. Richardson (Age 58)
Exec. VP & Chief Commercial Officer

Paul Nitschmann
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICPT shares.
View ICPT analyst ratings or view top-rated stocks.
What is Intercept Pharmaceuticals' stock price forecast for 2023?: 8 brokerages have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they predict the company's share price to reach $25.80 in the next twelve months. This suggests a possible upside of 82.1% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.
How have ICPT shares performed in 2022?: Intercept Pharmaceuticals' stock was trading at $16.29 at the start of the year. Since then, ICPT shares have decreased by 13.0% and is now trading at $14.17.
View the best growth stocks for 2022 here.
When is Intercept Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ICPT earnings forecast.
How were Intercept Pharmaceuticals' earnings last quarter?: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.89. The biopharmaceutical company earned $92.80 million during the quarter, compared to the consensus estimate of $83.04 million. Intercept Pharmaceuticals's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.01) EPS.
What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?: Intercept Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.00 million-$350.00 million, compared to the consensus revenue estimate of $312.94 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?: 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Intercept Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).
What is Intercept Pharmaceuticals' stock symbol?: Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
Who are Intercept Pharmaceuticals' major shareholders?: Intercept Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.09%), Vanguard Group Inc. (6.53%), Point72 Asset Management L.P. (3.76%), Jacobs Levy Equity Management Inc. (1.89%), Renaissance Technologies LLC (1.78%) and Macquarie Group Ltd. (1.58%). Insiders that own company stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Mark Pruzanski, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends.
How do I buy shares of Intercept Pharmaceuticals?: Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intercept Pharmaceuticals' stock price today?: One share of ICPT stock can currently be purchased for approximately $14.17.
How much money does Intercept Pharmaceuticals make?: Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $586.88 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or $5.74 on an earnings per share basis.
How many employees does Intercept Pharmaceuticals have?: The company employs 437 workers across the globe.
How can I contact Intercept Pharmaceuticals?: Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

Intercept Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™